All mouse models will be made available from JAX. For strains currently available, please see our Strain List.
All data describing novel models will be made available through the the AMP-AD Knowledge Portal www.ampadportal.org
Whole‐brain transcriptome data from staged model mice are available. Data include a range of genetic models based on genome‐wide association studies, including knockouts of APOE, BIN1, CLU, and CD2AP, knock‐in of human APOE4, Trem2R47H, and APOE4/Trem2R47H genotypes. This transcriptomic dataset also includes the new hA-KI model (JAX #30898) and transgenic models expressing familial AD mutations including the 5XFAD and APP/PS1 models. Functional and metabolic measures are available for APOE4, Trem2*R47H, and APOE4/Trem2*R47H models. Multiple biological replicates for both sexes and/or multiple ages are present for most strains.
One of the major challenges in the field of Alzheimer’s Disease is the translation of research performed in model organisms to productive clinical trials. The IU/JAX MODEL-AD group working in collaboration with AMP-AD and NanoString created and validated a 770 gene expression assay for the evaluation of mouse models of AD. The nCounter Mouse AD Panel provides an efficient, reproducible and cost-effective way to monitor disease progression with age, assay potential therapeutics, and screen compounds prior to more detailed pharmacodynamics analysis. IU/JAX MODEL-AD mouse models will be validated using the Mouse AD Panel, with all data made available on the AMP-AD Knowledge Portal. In addition to the Mouse AD Panel, the new Human AD panel is also now available to provide direct comparison of results derived in mouse models to human tissue and characterize AD with a comprehensive, standardized set of 770-genes. Researchers may also customize the panels with 30 additional RNA targets. For more information about NanoString, visit www.nanostring.com
All protocols used for phenotyping and preclinical testing will be made available as they are validated.
This workshop will leverage the expertise and facilities of the Indiana University (IU)/JAX Model Organism Development for Evaluation of Late Onset Alzheimer’s Disease (MODEL-AD) Precision Medicine consortium. We aim to address training gaps in preclinical drug screening by providing you with the skills and knowledge required for rigorous design, execution, analysis, and reporting of pharmacokinetic, pharmacodynamics, and preclinical efficacy experiments, particularly in the mouse. Through this workshop, you will experience a significant amount of hands-on, practical laboratory training in in vivo drug screening.